Analysts: Merck Shopping for Acquisitions to Repair Pipeline and 2 Other Dow Movers to Watch

Merck & Co. (NYSE:MRK): Current price $47.50

Analyst Alex Arfaei at the research firm BMO Capital has written in a note to investors that Allergan or Onyx might be acquisition targets by Merck, which would likely be responding to recent setbacks for its drug pipeline. What is more, Merck could be thinking about buying firms whose anticancer drugs complement its Lambro treatment, wrote Arafei, who added that Merck is evaluating Lambro as a treatment for several types of cancers, including non-small cell lung cancer, advanced melanoma, and hematological cancer.